Latest Glaucoma News

Page 2 of 2
Nova Eye Medical has reported a record A$29.2 million revenue for FY25, driven by strong sales growth and improved profitability in its glaucoma segment. The company targets breakeven EBITDA in the first half of FY26 alongside continued cash flow improvements.
Ada Torres
Ada Torres
29 July 2025
Nova Eye Medical has reported a record A$29.2 million revenue for FY25, driven by strong sales growth and improved profitability in its glaucoma segment. The company targets breakeven EBITDA in the first half of FY26 amid promising regulatory and market developments.
Ada Torres
Ada Torres
29 July 2025
Nova Eye Medical has reported a record A$28.8 million in revenues for FY25, driven by strong US sales and sustained growth of its flagship iTrack™ Advance device.
Ada Torres
Ada Torres
8 July 2025
Nova Eye Medical reported a 27% rise in Q3FY25 sales excluding China, driven by record US performance and a sharp reduction in glaucoma segment losses. The company confirmed FY25 revenue guidance and unveiled plans to expand its iTrack™ technology into ocular drug delivery.
Ada Torres
Ada Torres
29 Apr 2025
Nova Eye Medical Limited is raising A$6.6 million to strengthen its financial position following resolved supply chain disruptions, while reporting strong sales growth and nearing profitability in its glaucoma division.
Ada Torres
Ada Torres
31 Jan 2025
Nova Eye Medical has completed a $6.6 million placement to fund growth initiatives, supported by strong global sales growth and a major shareholder commitment. The capital raise aims to bolster sales teams and product development as the company targets profitability in its glaucoma division.
Victor Sage
Victor Sage
31 Jan 2025
Nova Eye Medical reports a robust 39% increase in global sales driven by strong U.S. market demand and secures $6.6 million in fresh capital to fuel expansion and product development.
Victor Sage
Victor Sage
31 Jan 2025
NeuroScientific Biopharmaceuticals has initiated critical IND-enabling studies for its glaucoma drug candidate EmtinB, backed by a solid cash position of A$4.5 million as of December 2024. Preliminary melanin binding results are shaping the path toward first-in-human trials.
Victor Sage
Victor Sage
30 Jan 2025